Tempest Therapeutics Inc (TPST NASDAQ) stock market data APIs
$0.9771
0.01(1%)
as of July 10, 2026
Try our APIs with
free plan!
Tempest Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Prev. Close
0.9771
Open
0.9841
High
1.0031
Low
0.9513
52 wk Range
0.95-12.23
Market Cap
15 577 K
Shares Outstanding
15 979 K
EPS
-0.5039
Beta
-1.707
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tempest Therapeutics Inc data using free add-ons & libraries
Get Tempest Therapeutics Inc Fundamental Data
Tempest Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -20 920 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Tempest Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-15
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tempest Therapeutics Inc News
New
Rani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure
(RTTNews) - Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. He succe...
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and...
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-t...
New Strong Buy Stocks for April 10th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Escalade, Incorporated ESCA: This sporting goods company has seen the Zacks Consensus Estimate for its current year earnings i...
Get Tempest Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
